Sorry, you need to enable JavaScript to visit this website.
Skip to main content

User menu

  • Sign in
  • Register

Main menu

  • Pfizer Medicines
  • Therapy Areas
  • News
  • Useful Resources
Pfizer Home
  • Pfizer Medicines
  • Therapy Areas
  • News
  • Useful Resources

News

  • News Archive

Search form

This site is intended only for healthcare professionals resident in the United Kingdom

The Role of Pharmacists In The Management of Osteoarthritis

Published by: By Pfizer Staff
Date of publishing: 9th Jan 2018
Osteoarthritis

Osteoarthritis (OA) is the most common type of arthritis and is estimated to affect around >40 million people across Europe.1 The condition has a lifetime risk of 45% for knee OA and 25% for hip OA.1 OA is the fastest growing cause of disability world-wide1, and with increased life expectancy and rising levels of obesity across Europe4, the condition is predicted to become the fourth leading cause of disability worldwide by 2020.1

What Is Osteoarthritis?

Osteoarthritis is a long-term chronic disease involving the thinning of cartilage in joints which results in bones rubbing together, creating stiffness, pain, and impaired movement.2 The joints most affected are the hands, knees, hips and spine. It is more prevalent with advancing age particularly if there is a family history.2 Women are also at a higher risk of getting the illness compared with men. Other risk factors include obesity, lack of exercise, joint injury and joint overuse (e.g. when participating in certain sports).2

The Role of Pharmacists

Pharmacists are frontline and accessible healthcare professionals who have access to patients five times more frequently than family physicians.2 Community pharmacists have proven they can address gaps in OA patient care.2 There is evidence to suggest that pharmacists administering a simple screening questionnaire can identify >80% of patients with knee pain who have undiagnosed knee OA.3Many people with OA are not diagnosed and are not referred for treatment. Pharmacists are ideally placed to screen for OA and make treatment recommendations, as they are often consulted about the choice of over-the-counter (OTC) analgesics to manage OA pain.1

Experts in the pharmacy profession recently compiled some recommendations based on a number of osteoarthritis management guidelines as they apply to pharmacists. Some key aspects from the recommendations are summarised below:

Screen for OA2

  • Guidelines suggest that OA can be diagnosed clinically, without further diagnostic or imaging tests, if the patient meets all of the following criteria:
    • Age 45 years or older
    • Activity-related joint pain
    • No morning joint-related stiffness or morning stiffness that lasts <30 minutes
    • Patients who do not meet these criteria may be referred by their primary care providers for imaging to rule out other serious joint conditions.
    • OA typically presents as a deep aching pain in a joint. There may be morning joint stiffness, typically lasting <30 minutes. Joints may also exhibit crepitus, enlargement, deformity and limited range of motion. Patients may present with a local inflammatory response, resulting in a tender, red, swollen and hot joint.
 

For patients who screen positive for OA2:

  • Provide arthritis education

    • Provide counselling on the signs and symptoms of OA
    • Provide OA information handouts and pamphlets

 

  • Provide a medication review and treatment recommendations in accordance with current OA guidelines

    • Conduct reviews of the patient’s prescription and OTC medications
    • Counsel patients on risks, benefits and appropriate use of medications to achieve maximum therapeutic benefit
 
  • Refer to allied health professionals as appropriate

    • Patients may benefit from referral to physiotherapists, dietitians and/or occupational therapists.

 

Management Options

The goal of therapy is to relieve symptoms of pain, improve joint function and mobility and improve quality of life while minimizing medication-related adverse events.2

In addition, pharmacists can educate patients and caregivers to help them understand their condition and work with both the patients and their primary health care provider to choose an appropriate therapy.2

Choice of treatment for OA is typically based on risk versus benefit, cost and patient preference. Pharmacological treatment options should always be used in combination with nonpharmacological options.2

Nonpharmacological management focuses on pharmacists recognizing the need for referral to other healthcare professionals to ensure the patient has access to appropriate specialized care. Non-pharmacological therapies with the most evidence for benefit and with consensus from guidelines include2:

  • patient education for self-management
  • land and water-based exercise and weight loss 
  • corrective footwear (particularly for those with knee OA)
  • assistive walking devices such as canes or walkers
  • transcutaneous electrical nerve stimulation (TENS) devices 
  • heat ,cold and massage (may reduce pain and stiffness in those with knee OA).

 

Pharmacists are in a unique position to be able to support patients with OA. Management guidelines highlighting pharmacist based interventions should equip the profession to support and improve the lives of those affected by the condition.2

 

References:

  1. Kingsbury SR, Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries, Rheumatology, Volume 53, Issue 5, 1 May 2014, Pages 937–947, accessed from: https://academic.oup.com/rheumatology/article/53/5/937/1798271 on 18/11/17

  2. Kielly J, Davies, EM, Practice guidelines for pharmacists: The management of osteoarthritis, Can Pharm J (Ott). 2017 May-Jun; 150(3): 156–168. Accessed from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415069/ on 18/11/17

  3. Marra CA, Cibere J et al, Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis,  Arthritis Rheum. 2007 Oct 15;57(7):1238-44, accessed from: https://www.ncbi.nlm.nih.gov/pubmed/17907209 on 18/11/17

 

 

Date of Preparation: March 2018
PP-GEP-GBR-1008
Pfizer Home
  • Pfizer Medicines
  • Therapy Areas
  • News
  • Useful Resources

News

  • News Archive

Janrain Capture

  • Register / Sign in

Footer menu

  • Report Adverse Events
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • Pfizer.co.uk

Copyright footer block

© 2018 Pfizer Limited. All rights reserved. PP-PFE-GBR-1078. Date of preparation: May 2018.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration  number GB201048427
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For healthcare professionals only*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select ‘No’, you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer’s prescription medicines.

*The ABPI Code definition of healthcare professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-GIP-GBR-3015 March 2018

YesNo
Your login attempt failed. Please try again.

{* message_withExistingAccount *}

{* loginWidget *}

{* message_joinNow *}

{* message_joinNowText *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* traditionalSignIn_createButton *}

{* message_signIn *}

Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* loginWidget *}
{* message_useAnotherAccount *}
Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* message_useAnotherAccount *}

{* message_registeringThankYou *}

{* message_confirmEmailSent *}

{* message_close *}

{* message_confirmTraditionalInformation *} {* message_alreadyHaveAccount *}

* Required Information

{* #registrationForm *} {* salutation *} {* givenName *} {* familyName *} {* email *} {* designation_name *} {* designation_specialty *} {* designation_specialty2 *} {* designation_specialty_json *} {* primaryAddress_workplace *} {* primaryAddress_postalCode *} {* phoneNumber_work *} {* license_number *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} {* acknowledgement_professional *} {* acknowledgement_consent *} {* acknowledgement_terms *}
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
{* hidden_programType *} {* hidden_campaign *} {* hidden_siteId *} {* hidden_preferredLanguage *} {* hidden_residencyCountry *}

PP-PFE-GBR-1083. Date of preparation May 2018
{* backButton *}
{* createAccountButton *}
{* /registrationForm *}
{*#postLoginAcceptanceForm*}

{* message_legalText *}

{* postLoginAcceptanceButton *}
{*/postLoginAcceptanceForm*}

{* message_emailPasswordResetInstructions *}

{* #forgotPasswordForm *} {* traditionalSignIn_emailAddress *}
{* backButton *}
{* forgotPassword_sendButton *}
{* /forgotPasswordForm *}

{* message_emailPasswordResetSent *}

{* message_close *}
{* mergeAccounts *}
{* #tradAuthenticateMergeForm *} {* traditionalSignIn_emailAddress *} {* mergePassword *}
{* backButton *}
{* traditionalSignIn_signInButton *}
{* /tradAuthenticateMergeForm *}